Roche CEO Warns Against 'Middle Ground' Approach To Combat Pricing Pressure
This article was originally published in The Pink Sheet Daily
Pressure will be greatest for firms with a less innovative or differentiated pipeline, Schwan told third quarter earnings call.
You may also be interested in...
Roche plans to file the selective CD20 antibody in 2016 after releasing positive Phase III data at ECTRIMS in both relapsing-remitting and primary progressive multiple sclerosis, a debilitating form of the disease for which there are no approved drugs.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.